Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
27.35
+0.02 (0.07%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,174,079
Profits / Employee
-$6,712
Market Cap
3.42B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Structure Therapeutics | 233 |
| Alumis | 227 |
| IDEAYA Biosciences | 145 |
| Parabilis Medicines | 145 |
| Tango Therapeutics | 137 |
ARQT News
- 8 days ago - Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board - TheFly
- 8 days ago - Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewsWire
- 9 days ago - Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - GlobeNewsWire
- 16 days ago - Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA - TheFly
- 16 days ago - FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - GlobeNewsWire
- 22 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - GlobeNewsWire
- 25 days ago - FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream - TheFly